103 related articles for article (PubMed ID: 26546525)
1. Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2015; 29(6):687-93. PubMed ID: 26546525
[TBL] [Abstract][Full Text] [Related]
2. Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2014; 28(5):867-70. PubMed ID: 25189901
[TBL] [Abstract][Full Text] [Related]
3. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
4. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
[TBL] [Abstract][Full Text] [Related]
5. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
6. No compensation in VEGF expression follows antisense suppression of BCL-2 activity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2012; 26(6):937-40. PubMed ID: 23160675
[TBL] [Abstract][Full Text] [Related]
7. BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents.
Shi XB; Gumerlock PH; Muenzer JT; deVere White RW
Cancer Biother Radiopharm; 2001 Oct; 16(5):421-9. PubMed ID: 11776759
[TBL] [Abstract][Full Text] [Related]
8. Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Sep; 29(3):2284-90. PubMed ID: 22038727
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
Rubenstein M; Guinan P
In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
[TBL] [Abstract][Full Text] [Related]
10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
11. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
13. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
14. BCL2 antisense reduces prostate cancer cell survival following irradiation.
Scott SL; Higdon R; Beckett L; Shi XB; deVere White RW; Earle JD; Gumerlock PH
Cancer Biother Radiopharm; 2002 Dec; 17(6):647-56. PubMed ID: 12537668
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2013; 30(3):599. PubMed ID: 23677569
[TBL] [Abstract][Full Text] [Related]
16. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
[TBL] [Abstract][Full Text] [Related]
17. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
18. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo.
Kausch I; Lingnau A; Endl E; Sellmann K; Deinert I; Ratliff TL; Jocham D; Sczakiel G; Gerdes J; Böhle A
Int J Cancer; 2003 Jul; 105(5):710-6. PubMed ID: 12740923
[TBL] [Abstract][Full Text] [Related]
19. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
20. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
